Opus Genetics(formerly Ocuphire Pharma)
Farmington Hills
About Opus Genetics(formerly Ocuphire Pharma)
Opus Genetics is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is currently focused on providing a novel once-daily eye drop treatment option, Nyxol, to treat multiple front-of-the-eye disorders, including night vision disturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $92.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2026)
- Ticker: fra:R3x1
- Website: opusgtx.com
- Phone: (248) 681-9815
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/opus-genetics-formerly-ocuphire-pharma-112305 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.